Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2006 Sep 8;56(5):641–648. doi: 10.1007/s00262-006-0225-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Springer-Verlag 2006

PMC Copyright notice

Fig. 1 — Metronomic CTX selectively depletes regulatory T cells (Treg) in cancer patients. a Circulating numbers of CD3⁺CD4⁺CD25^high per mm³ are determined by FACS analysis. The medians, 75 percentile (box) and SD (whiskers) are depicted for patients (n = 9, Table 1) before (D0) and 1 month after (D30) initiation of metronomic CTX and for healthy volunteers (HV) (n = 15). b Representation of Treg evolution as absolute number (left panel) and percentage of CD4⁺ T cells (right panel) during metronomic CTX regimen before (D0) and 1 month after (D30) initiation of metronomic CTX for each of the nine treated patients using FACS 3-color staining gating on CD3⁺CD4⁺CD25^high cells. c Multipanel representation of dot-blot analysis of CD4⁺CD25^high T cells in all patients during metronomic CTX regimen before (D0) and 1 month after (D30) initiation of metronomic CTX for each patients using FACS 3-color staining gating on CD3⁺CD4⁺CD25^high cells

Fig. 1 — Metronomic CTX selectively depletes regulatory T cells (Treg) in cancer patients. a Circulating numbers of CD3⁺CD4⁺CD25^high per mm³ are determined by FACS analysis. The medians, 75 percentile (box) and SD (whiskers) are depicted for patients (n = 9, Table 1) before (D0) and 1 month after (D30) initiation of metronomic CTX and for healthy volunteers (HV) (n = 15). b Representation of Treg evolution as absolute number (left panel) and percentage of CD4⁺ T cells (right panel) during metronomic CTX regimen before (D0) and 1 month after (D30) initiation of metronomic CTX for each of the nine treated patients using FACS 3-color staining gating on CD3⁺CD4⁺CD25^high cells. c Multipanel representation of dot-blot analysis of CD4⁺CD25^high T cells in all patients during metronomic CTX regimen before (D0) and 1 month after (D30) initiation of metronomic CTX for each patients using FACS 3-color staining gating on CD3⁺CD4⁺CD25^high cells